Get started
ERIS LIFESCIENCES LTDERIS LIFESCIENCES LTDERIS LIFESCIENCES LTD

ERIS LIFESCIENCES LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

ERIS chart


Full chart

ERIS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪171.03 B‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
52.35
Basic EPS (TTM)
24.20 INR
Net income (FY)
‪3.92 B‬ INR
Revenue (FY)
‪20.09 B‬ INR
Shares float
‪41.39 M‬
Beta (1Y)
0.76

Employees


Employees (FY)
‪3.08 K‬
Change (1Y)
−375 −10.85%
Revenue / Employee (1Y)
‪6.52 M‬ INR
Net income / Employee (1Y)
‪1.27 M‬ INR

About ERIS LIFESCIENCES LTD


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Amit Indubhushan Bakshi
Website
eris.co.in
Headquarters
Ahmedabad
Founded
2007
ISIN
INE406M01024
FIGI
BBG00GX73BH6
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ERIS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ERIS highest yielding bonds


B
BBGG5909067
Biocon Biologics Global Plc 6.67% 09-OCT-2029
Yield to maturity
8.47%
Maturity date
Oct 9, 2029
B
BBGG5909066
Biocon Biologics Global Plc 6.67% 09-OCT-2029
Yield to maturity
—
Maturity date
Oct 9, 2029
873ELL26
ELL-8.73%-7-12-26-PVT
Yield to maturity
—
Maturity date
Dec 7, 2026
873ELL27
EEL-8.73%-7-6-27-PVT
Yield to maturity
—
Maturity date
Jun 7, 2027

See all ERIS bonds 



Frequently Asked Questions


The current price of ERIS is 1,261.20 INR — it has decreased by −0.84% in the past 24 hours. Watch ERIS LIFESCIENCES LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange ERIS LIFESCIENCES LTD stocks are traded under the ticker ERIS.
ERIS stock has risen by 1.07% compared to the previous week, the month change is a −9.41% fall, over the last year ERIS LIFESCIENCES LTD has showed a 46.30% increase.
We've gathered analysts' opinions on ERIS LIFESCIENCES LTD future price: according to them, ERIS price has a max estimate of 1,700.00 INR and a min estimate of 1,270.00 INR. Watch ERIS chart and read a more detailed ERIS LIFESCIENCES LTD stock forecast: see what analysts think of ERIS LIFESCIENCES LTD and suggest that you do with its stocks.
ERIS reached its all-time high on Dec 11, 2024 with the price of 1,593.90 INR, and its all-time low was 321.00 INR and was reached on Mar 13, 2020. View more price dynamics on ERIS chart.
See other stocks reaching their highest and lowest prices.
ERIS stock is 1.76% volatile and has beta coefficient of 0.76. Track ERIS LIFESCIENCES LTD stock price on the chart and check out the list of the most volatile stocks — is ERIS LIFESCIENCES LTD there?
Today ERIS LIFESCIENCES LTD has the market capitalization of ‪171.08 B‬, it has decreased by −0.68% over the last week.
Yes, you can track ERIS LIFESCIENCES LTD financials in yearly and quarterly reports right on TradingView.
ERIS LIFESCIENCES LTD is going to release the next earnings report on May 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ERIS LIFESCIENCES LTD revenue for the last quarter amounts to ‪7.28 B‬ INR, despite the estimated figure of ‪7.47 B‬ INR. In the next quarter, revenue is expected to reach ‪7.86 B‬ INR.
ERIS net income for the last quarter is ‪836.30 M‬ INR, while the quarter before that showed ‪915.90 M‬ INR of net income which accounts for −8.69% change. Track more ERIS LIFESCIENCES LTD financial stats to get the full picture.
ERIS LIFESCIENCES LTD dividend yield was 0.00% in 2023, and payout ratio reached 0.00%. The year before the numbers were 1.28% and 26.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Mar 17, 2025, the company has ‪3.08 K‬ employees. See our rating of the largest employees — is ERIS LIFESCIENCES LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ERIS LIFESCIENCES LTD EBITDA is ‪9.13 B‬ INR, and current EBITDA margin is 34.88%. See more stats in ERIS LIFESCIENCES LTD financial statements.
Like other stocks, ERIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ERIS LIFESCIENCES LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ERIS LIFESCIENCES LTD technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ERIS LIFESCIENCES LTD stock shows the buy signal. See more of ERIS LIFESCIENCES LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.